


WE CLAIM:

1. A compound of the formula (I):




or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A and B are independently O, S, NR⁷ or CR⁷R⁸;
- (c) R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR⁹ (wherein X = O, S or NR¹⁰);
- (d) alternatively, one or more of R¹ and R², R² and R³, R³ and R⁴, R⁴ and R⁵, or R⁵ and R⁶, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R⁷, R⁸, R⁹ and R¹⁰ is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

2. A compound of the formula (II)




or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A, B and D are independently O, S, NR⁷ or CR⁷R⁸;
- (c) R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR⁹ (wherein X = O, S or NR¹⁰);
- (d) alternatively, one or more of R¹ and R², R² and R³, R³ and R⁴, R⁴ and R⁵, or R⁵ and R⁶, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R⁷, R⁸, R⁹ and R¹⁰ is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

3. A compound of the formula (III):




or its pharmaceutically acceptable salt thereof, wherein:

- (a) A, B, D and E are independently O, S, NR^7 or CR^7R^8 ;
- (b) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});
- (c) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (d) each R^7 , R^8 , R^9 and R^{10} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

4. A compound of the formula (IV):




or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A, B and E are independently O, S, NR^7 or CR^7R^8 ;
- (c) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}$, S or NR^{10});
- (d) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R^7 , R^8 , R^9 and R^{10} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate

optionally in a pharmaceutically acceptable carrier.

5. A compound of the formula (V):




or its pharmaceutically acceptable salt thereof, wherein:

- (a) B, D and E are independently O, S, NR^7 or CR^7R^8 ;
- (b) G is OR^{11} , $\text{NR}^{11}\text{R}^{12}$ or SR^{11} ;

- (c) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $X = O, S$ or NR^{10});
- (d) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate

optionally in a pharmaceutically acceptable carrier.

6. A compound of the formula (VI):



or its pharmaceutically acceptable salt thereof, wherein:


- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) B is O, S, NR^7 or CR^7R^8 ;
- (c) G is $OR^{11}, NR^{11}R^{12}$ or SR^{11} ;
- (d) R^1, R^2, R^3, R^4, R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl,

heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});

- (e) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

7. A compound of the formula (VII):



or its pharmaceutically acceptable salt thereof, wherein:


- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A and B are independently $\text{O}, \text{S}, \text{NR}^7$ or CR^7R^8 ;
- (c) $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5$ and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl,

phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});

- (d) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R^7 , R^8 , R^9 and R^{10} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

8. A compound of the formula (VIII):



or its pharmaceutically acceptable salt thereof, wherein:


- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) B and E are independently $\text{O}, \text{S}, \text{NR}^7$ or CR^7R^8 ;
- (c) G is OR^{11} , $\text{NR}^{11}\text{R}^{12}$ or SR^{11} ;
- (d) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphoryl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a

residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});

- (e) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

9. A compound of the formula (IX):



(IX)


or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) E is $\text{O}, \text{S}, \text{NR}^7$ or CR^7R^8 ;
- (c) G is OR^{11} , $\text{NR}^{11}\text{R}^{12}$ or SR^{11} ;
- (d) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});

- (e) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

10. A compound of the formula (X):



or its pharmaceutically acceptable salt thereof, wherein:


- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A is O, S, NR^7 or CR^7R^8 ;
- (c) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $X = O, S$ or NR^{10});
- (d) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5,

6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

- (e) each R^7 , R^8 , R^9 and R^{10} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.


11. A compound of the formula (XI):



or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A and E are independently O, S, NR^7 or CR^7R^8 ;
- (c) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $X = O, S$ or NR^{10});
- (d) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and

- (e) each R^7 , R^8 , R^9 and R^{10} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate; optionally in a pharmaceutically acceptable carrier.
12. A compound of the formula (XII):



(XII)


or its pharmaceutically acceptable salt thereof, wherein:

- the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- A, D and E are independently O, S, NR^7 or CR^7R^8 ;
- R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein X = O, S or NR^{10});
- alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- each R^7 , R^8 , R^9 and R^{10} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl,

heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

13. A compound of the formula (XIII):




or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A and D are independently O, S, NR^7 or CR^7R^8 ;
- (c) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});
- (d) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R^7 , R^8 , R^9 and R^{10} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

14. A compound of the formula (XIV):




or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) B is O, S, NR^7 or CR^7R^8 ;
- (c) G is OR^{11} , $\text{NR}^{11}\text{R}^{12}$ or SR^{11} ;
- (d) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});
- (e) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

15. A compound of the formula (XV):




or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) B and D are independently O, S, NR^7 or CR^7R^8 ;
- (c) G is OR^{11} , $\text{NR}^{11}\text{R}^{12}$ or SR^{11} ;
- (d) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});
- (e) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

16. A compound of the formula (XVI):




(XVI)

or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) D is O, S, NR^7 or CR^7R^8 ;
- (c) G is OR^{11} , $\text{NR}^{11}\text{R}^{12}$ or SR^{11} ;
- (d) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});
- (e) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

17. A compound of the formula (XVII):




(XVII)

or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) D and E are independently O, S, NR^7 or CR^7R^8 ;
- (c) G is OR^{11} , $\text{NR}^{11}\text{R}^{12}$ or SR^{11} ;
- (d) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $\text{X} = \text{O}, \text{S}$ or NR^{10});
- (e) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

18. A compound of the formula (XVIII):




(XVIII)

or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) G is OR^{11} , $NR^{11}R^{12}$ or SR^{11} ;
- (c) R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR^9 (wherein $X = O, S$ or NR^{10});
- (d) alternatively, one or more of R^1 and R^2 , R^2 and R^3 , R^3 and R^4 , R^4 and R^5 , or R^5 and R^6 , come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R^7 , R^8 , R^9 , R^{10} , R^{11} and R^{12} is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

19. A compound of the formula (XIX):




(XIX)

or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) A, B and M are independently O, S, NR⁷ or CR⁷R⁸;
- (c) R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR⁹ (wherein X = O, S or NR¹⁰);
- (d) alternatively, one or more of R¹ and R², R² and R³, R³ and R⁴, R⁴ and R⁵, or R⁵ and R⁶, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (e) each R⁷, R⁸, R⁹ and R¹⁰ is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

20. A compound of the formula (XX):



or its pharmaceutically acceptable salt thereof, wherein:

- (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) B and M are independently O, S, NR⁷ or CR⁷R⁸;
- (c) G is OR¹¹, NR¹¹R¹² or SR¹¹;
- (d) R¹, R², R³, R⁴, R⁵ and R⁶ are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, carbonyl, carboxylic acid, ester, carbamate, amide, amine, hydroxyl, alkoxide, nitro, cyano, azide, sulfonyl, sulfanyl, sulfinyl, sulfamonyl, phosphonyl, phosphinyl, phosphoryl, phosphine, a residue of a natural or synthetic amino acid, a residue of a natural or synthetic carbohydrate or XR⁹ (wherein X = O, S or NR¹⁰);
- (e) alternatively, one or more of R¹ and R², R² and R³, R³ and R⁴, R⁴ and R⁵, or R⁵ and R⁶, come together to form a bridged compound, preferably as a 3, 5, 6 or 7 membered ring, to form a cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heterocyclic, heteroaryl or heteroaromatic; and
- (f) each R⁷, R⁸, R⁹, R¹⁰, R¹¹ and R¹² is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl, heterocyclic, heteroaryl, heteroaromatic, alkcarbonyl, a residue of a natural or synthetic amino acid or a residue of a natural or synthetic carbohydrate;

optionally in a pharmaceutically acceptable carrier.

21. A method for the treatment or prophylaxis of an inflammatory disorder in a host comprising administering an effective treatment amount of a compound according to any one of claim 1-20.
22. A method for the treatment or prophylaxis of an autoimmune disorder in a host comprising administering an effective treatment amount of a compound according to any one of claim 1-20.

10
 20
 30
 40
 50
 60
 70
 80
 90
 100
 110
 120
 130
 140
 150
 160
 170
 180
 190
 200
 210
 220
 230
 240
 250
 260
 270
 280
 290
 300
 310
 320
 330
 340
 350
 360
 370
 380
 390
 400
 410
 420
 430
 440
 450
 460
 470
 480
 490
 500
 510
 520
 530
 540
 550
 560
 570
 580
 590
 600
 610
 620
 630
 640
 650
 660
 670
 680
 690
 700
 710
 720
 730
 740
 750
 760
 770
 780
 790
 800
 810
 820
 830
 840
 850
 860
 870
 880
 890
 900
 910
 920
 930
 940
 950
 960
 970
 980
 990
 1000